Factors related to post‐treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy

• DOI: 10.1111/j.1440-1746.2005.03952.x
• Publication Date: 2005-11-11T14:41:53Z
• Authors: KWAN SOO BYUN; OH SANG KWON; JU HYUN KIM; HYUNG JOON YIM; YUN JUNG CHANG; JIN YONG KIM; JONG EUN YEON; JONG JAE PARK; JAE SEON KIM; YOUNG TAE BAK; CHANG HONG LEE
• Keywords: HBeAg; Hepatitis B

It is uncertain if a patient's lamivudine response after HBeAg loss durable. In Korean chronic hepatitis B patients, the relapse rate high termination of therapy for patients with loss. We evaluated factors related to in therapy.A total 132 who initially had and did not have decompensated features, were analyzed this study. These lost then their was stopped. Post-treatment serum alanine aminotransferase (ALT), HBeAg, anti-HBe virus (HBV) DNA monitored until relapse.Seventy-five relapsed (cumulative rate: 56% at 6 months). Upon univariate analysis, age, bilirubin, presence loss, duration additional associated relapse. multivariate older higher bilirubin shorter significant risk Patterns re-elevation ALT, re-emergence HBV (69 patients) reappearance (55 patients).To prevent infection therapy, age level as well prolonged should be considered.